InvestorsHub Logo
Followers 23
Posts 1330
Boards Moderated 1
Alias Born 09/25/2018

Re: thermo post# 425750

Saturday, 12/11/2021 12:52:17 PM

Saturday, December 11, 2021 12:52:17 PM

Post# of 692405
Some of your observations are why traditional quant factors fail in biotech.

Consider a high profile small biotech with a few analysts covering it. Their P1 is successful, so on to P2. While this is unambiguously good news, the estimate revision factor will be negative instead of positive.

Revenues are still many years away. Expenses for FY1 and FY2 will ramp up. So current and next year earnings will be more negative.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News